Syncom Formulations (India) Limited

AV1lOGMP6lSOsaol-2WB~Comprq

CIN:L24239MH1988PLCO47759
SYNCOM/SE/2016
To,
The General Manager
DCS-CRD
BSE Ltd.
Dalal Street, Fort,
MUMBAI-40000 1

online filing at listing.bseindia.com

14" Nov., 2016

BSE CODE: 524470

Sob: Submission of the Unaudited Standalone Financial Results for the quarterhalf year ended
3 0 ' ~September, 2016 as per Regulation 33 of SEBI (LODR) Regulation, 2015.
Dear Sir,
This has in continuation of our letter No. SYNCOWSEl2016 dated 3rd Nov., 2016 regarding information
for Board meeting for consideration of the quarterly/half yearly Standalone Unaudited Financial Results
for the Quarter1 Half year ended 3 0 September,
~
2016.
We are pleased to inform that the Board of Directors of the Company has considered and approved the
quarterlyhalf yearly Unaudited Standalone Financial Results for the quarterhalf year ended 30th
September, 2016 at their Meeting held on Monday, 14" Nov., 2016 in accordance with the Regulation 33
of SEBI (LODR) Regulati*, 2015.
We also submit a copy of the above said Financial Results for the quarter ended 30th September, 2016 for
your reference and records.
The above results will be published in Marathi (vernacular) and widely circulated English Newspaper.
You are requested to taken on record the above said financial results for your reference and record.
Thanking
- You,
RMULATIONS (INDIA) LTD.

SYNCOM FORMULATIONS (INDIA) LTD.

Regd. Of.: 7, Niraj IndustrialEstate, Off Mahakali Caves Road, Andheri (E), MUMBAI -400 093

Works :256-257, Sector I,Pithampur (Dhar), E-mail:info@sfil.in, CIN : L24239MH1988PLC047759

Total Income from Operation

(c) Changes in inventories

income, finance costs and exceptional items

beforeextraordinaryitems(in ll-each)(notannualised
a)Basic Earningper share

(after extraordinaryaems (in 11-each) (notannuaiised)

a) BasicEarningpershare
b) DilutedEarningPerShare

Particulars

Less: Inter Segment Revenue

(a) Pharmaceuticals Drugs & Formulations

(b) Trading of Commodities

(ii) Other Un-allocable Expenditure net off

(iii) Un-allocablelnwme

Total Profit Before Tax

3 Capital Employed
(Segment Assets - Segment Liabilities)
(a) Pharmaceuticals Drugs & Formulations
(b) Trading of Commodities
(c) Renting of Pmperty

(djUnaliacated

Total Capital Employed

SYNCOM FORMULATIONS (INDIA) LTD.

Regd. Off.: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E), MUMBAI -400 093
Works :256.257, Sector. I,Pithampur (Dhar), E-mail :info@sfil.in, CIN : L24239MH1988PLC047759

1
I

STATEMENT OF ASSETS & LIABILITY AS AT 30109/2016

1 AS AT 30.09.2016 1

Particulars

I A. IEQUITY AND LIABILITIES

(Unaudited)

(Rs. in lacs]

AS AT 31.03.2016
(Audited)

II

Shares holders' fund

la) Share caoitai
(bj Reserve and surplus
(c) Money received against share warrants
Sub total -shareholders1funds
Share application money pending allotment
Minority interest
Non-current liabilities
(a) Long-term borrowing
(b) Deferred tax liabilities (net)
(c) Long-term liabilities
(d) Long-term provisions
Sub total noncurrent liabilities
Current liabilities
(a) Short-term borrowing
(b) Trade ~avables
Iicj Other cuirent liabilities
Short-term provisions
Sub total noncurrent liabilities
TOTAL - EQUITY AND LIABILITI@
B. ASSETS
Non-current assets
(a) Fixed assets
(b) Goodwill on consolidation
(c) Non-current investments
(d) Deferred tax assets (net)
(e) Long-term loans and advances
(f) Other non-current assets
Sub total - noncurrent assets
Current assets
(a) Current investments
(b) inventories
(c) Trade receivables
(d) Cash and cash equivalents
(e) Short-term loans and advances
(9' Other current assets
Sub total -current assets
TOTAL ASSETS

Iid)

68.33
7517.07
16792.31

Notes:
1. The above Unaudited Financial Results were reviewed and recommended by the Audit Committeeand taken on record by the Board of
Directorsattheir meetings held on 14th November2016.
2. The limited review under regulation 33 of the SEE1 (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been
carried out by the Statutory Auditors. The report does not contain anything which would have an impact on the results for the Quarter
ended 30th September2016.
2. The company is operating in three segment i.e.: (a.)Pharmaceutical Drugs &
(c) Renting of
Property.
3. Figuresforthe previous periodslyear have been regroupedwherever

.. .

Place : Indore
Dated : 14/11/2016

'armal B

@&mpn
...

*%.

+:.

;:.,,

ij

dd 6
& whol<ti$e

*:

,LY'

Director

Syncom Formulations (India) Limited

A m K K m P & I S O W l - ~ e a r W ~

CIN L24239MH1988PLC047759
1 4 Nov.,
~ 2016
Online Filing at listinp.bseindia.com
To,
The General Manager
DCS-CRD
Bombay Stock Exchange Ltd.
Dalal Street, Fort,
MUMBAI-400001
BSE CODE: 524470
Subject: Filing of Limited Review Report by the Auditors on the Unaudited Standalone
Financial ~ e s u l t for
s the Quarter/ Half Year Ended 3othSeptember, 2016 under Regulation
33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Dear Sir,
Please find enclosed the Limited Review Report given by the Auditors on the Standalone
Unaudited Financial Results for the QuarterIHalf Year ended 30' September, 2016 pursuant to
Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015, which wqs also $nsidered and approved by the Board of Directors of the Company at
their meeting held on 14 November, 2016.
Since the report is self-explanatory and having no material difference in the provisional result
declared by the Company, with the Limited Review Report for the above said period, it needs no
comrnents/explanation by the Board.
You are requested to kindly take the same on record for your further needful.
Thanking You,
ULATIONS (INDIA) LTD.

Encl.: ala

S.P.MOONDRA
F.C.A.

S.P. MOONDRA & CO.

CHARTEREDACCOUNTANTS
5318,Kanchan Bagh INDORE-1,
Ph.(0731) 2513817,4066330

THE LIMITED REVIEW REPORT OF SYNCOM FORMULATIONS (INDIA) LTD

FOR THE QUARTERLY STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE

QUARTER AND HALF YEAR ENDED 30TnSEPTEMBER. 2016

TO
THE BOARD OF DIRECTORS
SYNCOM FORMULATIONS (INDIA) LTD.
We have reviewed the accompanying statement of Unaudited Financial Results of Syncom
Formulations (India) Limited for the quarterlhalf year ended 3OmSeptember, 2016 This
statement is the responsibility of the Company's Management and has been approved by the
Board of Directors. Our responsibility is to issue a report on these financial statements based on
our review.
We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400,
Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of
lndia.-~hisstandard requires that we plan and perform-the review to obtain moderate assurance
as to whether the financial statements are free of material misstatement. A review is limited
primarily to inquiries of qmpany personnel and analytical procedures applied to financial data
and thus provides less assurance than an audit. We have not performed an audit and accordingly,
we do not express an audit opinion.
Based on our review conducted as above, nothing has come to our attention that causes us to
believe that the accompanying statement of unaudited financial results prepared in accordance
with applicable accounting standards and other recognized accounting practices and policies has
not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in
which it is to be disclosed, or that it contains any material misstatement.
FOR S.P. MOONDRA & CO.

PLACE: INDORE
DATE : 14TnNOVEMBER' 2016